Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (24)

« Back to Publications

The impact of pausing Bruton Tyrosine Kinase inhibitor (BTKi) therapy versus continued therapy on vaccination immune response in patients with chronic lymphocytic leukaemia: the IMPROVE RCT

Cook JA. et al, (2025), Efficacy and Mechanism Evaluation, 1 - 25

Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 1 - 42

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 47 - 48

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 45 - 46

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 43 - 44

Streamlining electronic reporting of serious adverse events (SAEs) using the REDCap data collection system: the eSAE Project.

Black J. et al, (2024), Trials, 25

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.

Abhishek A. et al, (2024), Lancet Rheumatol, 6, e92 - e104

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial

Abhishek A. et al, (2023), Lancet Rheumatology, 6, e92 - e104

How should we best measure participant-reported ‘average hand pain’: comparison of two methods from a randomized placebo-controlled feasibility study of post-menopausal women with hand osteoarthritis

Williams JA. et al, (2023), Osteoarthritis and Cartilage, 31, s187 - s188

Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, feasibility study.

Williams JAE. et al, (2022), Lancet Rheumatol, 4, e725 - e737

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.

Abhishek A. et al, (2022), Lancet Respir Med, 10, 840 - 850

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial

Abhishek A. et al, (2022), Lancet Respiratory Medicine, 10, 840 - 850

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study).

Abhishek A. et al, (2022), BMJ Open, 12

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.

Rosmarin D. et al, (2015), Gut, 64, 111 - 120

Load More